Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Dongjak-Gu, Korea, Republic of Clinical Trials

A listing of Dongjak-Gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (184) clinical trials

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.

Phase N/A

0.53 miles

Learn More »

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 3000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in ...

Phase N/A

0.53 miles

Learn More »

Exploring Biological Linkage Between Circadian Disruption and Cancer Progression

The biological markers that are assumed to bridge this association are measured and analyzed.

Phase N/A

1.58 miles

Learn More »

Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive

To evaluate safety and efficacy of CE/BZA in real practice in Korea

Phase N/A

1.92 miles

Learn More »

Post Marketing Surveillance Study For Sayana

Post Marketing Surveillance required by Korea MFDS regulation. Select among patients who randomly visit the site who meet the inclusion/exclusion criteria.

Phase N/A

1.92 miles

Learn More »

An Observational Study of Herceptin SC Safety in Breast Cancer

This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.

Phase N/A

1.92 miles

Learn More »

An Observational Study of Kadcyla Safety in Breast Cancer

This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 3,000 patients who are to receive Kadcyla (trastuzumab emtansine). Patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with trastuzumab and a taxane, and administered Kadcyla infusion at physician's discretion ...

Phase N/A

1.92 miles

Learn More »

Apoptosis in Polymorphonuclear Cells and Inflammatory Cytokines of Trauma Patients

Many patients visit an emergency room because of their trauma. Trauma patients account for around 25-35% in an emergency room. Trauma is the biggest cause of acquired disabilities, and is greatly related to death and disabilities of those aged less than 44. As such, since trauma leads to lowering personal ...

Phase N/A

1.92 miles

Learn More »

Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ

The objective of this study is to determine any problems or questions associated with Pristiq after marketing, with regard to the following clauses under conditions of general clinical practice, in compliance with the regulation "Re-examination guideline of new drugs (Ministry of Food and Drug Safety Notification 2013-251, 2013.12.20)". Serious adverse ...

Phase N/A

1.92 miles

Learn More »

Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy

The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination ...

Phase N/A

1.92 miles

Learn More »